vs
Side-by-side financial comparison of LSB INDUSTRIES, INC. (LXU) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $169.5M, roughly 1.8× LSB INDUSTRIES, INC.). Bio-Techne runs the higher net margin — 16.4% vs 11.6%, a 4.8% gap on every dollar of revenue. On growth, LSB INDUSTRIES, INC. posted the faster year-over-year revenue change (18.2% vs -1.5%). Over the past eight quarters, LSB INDUSTRIES, INC.'s revenue compounded faster (10.0% CAGR vs 1.3%).
Eldridge Industries, LLC is an American holding company headquartered in Miami, with offices in New York City, Greenwich, Connecticut, London, and Beverly Hills. It invests in industries such as insurance, asset management, technology, sports, media, real estate, and the consumer sector.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
LXU vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $169.5M | $311.4M |
| Net Profit | $19.7M | $51.0M |
| Gross Margin | 21.1% | 66.9% |
| Operating Margin | 13.7% | 24.2% |
| Net Margin | 11.6% | 16.4% |
| Revenue YoY | 18.2% | -1.5% |
| Net Profit YoY | — | 126.0% |
| EPS (diluted) | — | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $169.5M | $311.4M | ||
| Q4 25 | $165.0M | $295.9M | ||
| Q3 25 | $155.4M | — | ||
| Q2 25 | $151.3M | $317.0M | ||
| Q1 25 | $143.4M | $316.2M | ||
| Q4 24 | $134.9M | $297.0M | ||
| Q3 24 | $109.2M | $289.5M | ||
| Q2 24 | $140.1M | $306.1M |
| Q1 26 | $19.7M | $51.0M | ||
| Q4 25 | $16.1M | $38.0M | ||
| Q3 25 | $7.1M | — | ||
| Q2 25 | $3.0M | $-17.7M | ||
| Q1 25 | $-1.6M | $22.6M | ||
| Q4 24 | $-9.1M | $34.9M | ||
| Q3 24 | $-25.4M | $33.6M | ||
| Q2 24 | $9.6M | $40.6M |
| Q1 26 | 21.1% | 66.9% | ||
| Q4 25 | 25.0% | 64.6% | ||
| Q3 25 | 16.4% | — | ||
| Q2 25 | 15.3% | 62.7% | ||
| Q1 25 | 10.0% | 67.9% | ||
| Q4 24 | 4.5% | 65.3% | ||
| Q3 24 | -7.3% | 63.2% | ||
| Q2 24 | 19.6% | 66.4% |
| Q1 26 | 13.7% | 24.2% | ||
| Q4 25 | 16.2% | 18.4% | ||
| Q3 25 | 10.1% | — | ||
| Q2 25 | 6.9% | -7.5% | ||
| Q1 25 | 3.1% | 12.2% | ||
| Q4 24 | -5.0% | 16.0% | ||
| Q3 24 | -22.4% | 13.8% | ||
| Q2 24 | 10.3% | 15.0% |
| Q1 26 | 11.6% | 16.4% | ||
| Q4 25 | 9.8% | 12.8% | ||
| Q3 25 | 4.6% | — | ||
| Q2 25 | 2.0% | -5.6% | ||
| Q1 25 | -1.1% | 7.1% | ||
| Q4 24 | -6.8% | 11.7% | ||
| Q3 24 | -23.2% | 11.6% | ||
| Q2 24 | 6.8% | 13.3% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $0.22 | $0.24 | ||
| Q3 25 | $0.10 | — | ||
| Q2 25 | $0.04 | $-0.11 | ||
| Q1 25 | $-0.02 | $0.14 | ||
| Q4 24 | $-0.13 | $0.22 | ||
| Q3 24 | $-0.35 | $0.21 | ||
| Q2 24 | $0.13 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $181.7M | $209.8M |
| Total DebtLower is stronger | $770.0K | — |
| Stockholders' EquityBook value | $542.9M | $2.1B |
| Total Assets | $1.2B | $2.6B |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $181.7M | $209.8M | ||
| Q4 25 | $148.5M | $172.9M | ||
| Q3 25 | $152.0M | — | ||
| Q2 25 | $124.9M | $162.2M | ||
| Q1 25 | $163.5M | $140.7M | ||
| Q4 24 | $184.2M | $177.5M | ||
| Q3 24 | $199.3M | $187.5M | ||
| Q2 24 | $216.3M | $152.9M |
| Q1 26 | $770.0K | — | ||
| Q4 25 | $440.3M | $260.0M | ||
| Q3 25 | $447.6M | — | ||
| Q2 25 | $446.4M | $346.0M | ||
| Q1 25 | $478.2M | $330.0M | ||
| Q4 24 | $476.2M | $300.0M | ||
| Q3 24 | $476.0M | $300.0M | ||
| Q2 24 | $479.8M | $319.0M |
| Q1 26 | $542.9M | $2.1B | ||
| Q4 25 | $520.0M | $2.0B | ||
| Q3 25 | $504.6M | — | ||
| Q2 25 | $495.8M | $1.9B | ||
| Q1 25 | $490.6M | $2.0B | ||
| Q4 24 | $491.6M | $2.1B | ||
| Q3 24 | $499.0M | $2.1B | ||
| Q2 24 | $522.8M | $2.1B |
| Q1 26 | $1.2B | $2.6B | ||
| Q4 25 | $1.2B | $2.5B | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | $2.6B | ||
| Q1 25 | $1.2B | $2.6B | ||
| Q4 24 | $1.2B | $2.7B | ||
| Q3 24 | $1.2B | $2.7B | ||
| Q2 24 | $1.2B | $2.7B |
| Q1 26 | 0.00× | — | ||
| Q4 25 | 0.85× | 0.13× | ||
| Q3 25 | 0.89× | — | ||
| Q2 25 | 0.90× | 0.18× | ||
| Q1 25 | 0.97× | 0.16× | ||
| Q4 24 | 0.97× | 0.14× | ||
| Q3 24 | 0.95× | 0.14× | ||
| Q2 24 | 0.92× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LXU
| AN & Nitric Acid | $75.3M | 44% |
| Urea ammonium nitrate (UAN) | $49.2M | 29% |
| Ammonia | $36.8M | 22% |
| Other | $8.2M | 5% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
